ATE454382T1 - Verbindungen mit selektiverinhibierender wirkung für gsk3 - Google Patents

Verbindungen mit selektiverinhibierender wirkung für gsk3

Info

Publication number
ATE454382T1
ATE454382T1 AT03781204T AT03781204T ATE454382T1 AT E454382 T1 ATE454382 T1 AT E454382T1 AT 03781204 T AT03781204 T AT 03781204T AT 03781204 T AT03781204 T AT 03781204T AT E454382 T1 ATE454382 T1 AT E454382T1
Authority
AT
Austria
Prior art keywords
compounds
alkylnr
gsk3
alkylc
solvate
Prior art date
Application number
AT03781204T
Other languages
English (en)
Inventor
Stefan Berg
Sven Hellberg
Peter Soederman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE454382T1 publication Critical patent/ATE454382T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT03781204T 2002-12-17 2003-12-15 Verbindungen mit selektiverinhibierender wirkung für gsk3 ATE454382T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0203754A SE0203754D0 (sv) 2002-12-17 2002-12-17 New compounds
PCT/SE2003/001955 WO2004055005A1 (en) 2002-12-17 2003-12-15 Novel compounds having selective inhibiting effect at gsk3

Publications (1)

Publication Number Publication Date
ATE454382T1 true ATE454382T1 (de) 2010-01-15

Family

ID=20289907

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03781204T ATE454382T1 (de) 2002-12-17 2003-12-15 Verbindungen mit selektiverinhibierender wirkung für gsk3

Country Status (19)

Country Link
US (2) US7585853B2 (de)
EP (2) EP1575938B1 (de)
JP (1) JP4674088B2 (de)
KR (1) KR101110457B1 (de)
CN (1) CN100351250C (de)
AT (1) ATE454382T1 (de)
AU (1) AU2003287135B2 (de)
BR (1) BR0317294A (de)
CA (1) CA2508042C (de)
DE (1) DE60330910D1 (de)
ES (1) ES2337682T3 (de)
HK (1) HK1080856A1 (de)
IL (1) IL169016A (de)
MX (1) MXPA05006243A (de)
NO (1) NO331495B1 (de)
NZ (1) NZ540449A (de)
SE (1) SE0203754D0 (de)
WO (1) WO2004055005A1 (de)
ZA (1) ZA200504617B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203752D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
WO2006021884A2 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
PT1784396E (pt) * 2004-08-26 2011-01-27 Pfizer Compostos amino-heteroarílicos substituídos com pirazole como inibidores de proteína quinases
JPWO2008156174A1 (ja) * 2007-06-21 2010-08-26 大正製薬株式会社 ピラジンアミド化合物
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2138485A1 (de) * 2008-06-26 2009-12-30 sanofi-aventis Substituierte N-Oxid-Pyrazin-Derivate
RU2011123647A (ru) 2008-11-10 2012-12-20 Вертекс Фармасьютикалз Инкорпорейтед Соединения, полезные в качестве ингибиторов atr киназы
SG172248A1 (en) 2008-12-19 2011-07-28 Vertex Pharma Pyrazine derivatives useful as inhibitors of atr kinase
WO2011059388A1 (en) * 2009-11-13 2011-05-19 Astrazeneca Ab Oxazolo[4,5-c]pyridine substituted pyrazine
WO2011089416A1 (en) * 2010-01-19 2011-07-28 Astrazeneca Ab Pyrazine derivatives
WO2011143419A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
CA2798763A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2569287B1 (de) 2010-05-12 2014-07-09 Vertex Pharmaceuticals Inc. Verbindungen als hemmer der atr-kinase
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2569284B1 (de) 2010-05-12 2015-07-08 Vertex Pharmaceuticals Incorporated 2-aminopyridinderivate als atr-kinaseinhibitoren
WO2011143399A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
NZ605627A (en) 2010-06-23 2015-06-26 Vertex Pharma Pyrrolo-pyrazine derivatives useful as inhibitors of atr kinase
WO2012138938A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
LT2714668T (lt) 2011-05-23 2017-04-10 Merck Patent Gmbh Tiazolo dariniai
CA2832605C (en) 2011-05-23 2016-03-29 Merck Patent Gmbh Pyridine-and pyrazine derivatives
EP2723747A1 (de) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Als art-kinasehemmer nützliche verbindungen
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2012178123A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
DE102011112978A1 (de) 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
EP3878851A1 (de) 2011-09-30 2021-09-15 Vertex Pharmaceuticals Incorporated Verfahren zur herstellung von verbindungen welche als hemmer der atr-kinase nützlich sind
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846686B2 (en) 2011-09-30 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN103957917A (zh) 2011-09-30 2014-07-30 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776419B1 (de) 2011-11-09 2016-05-11 Vertex Pharmaceuticals Incorporated Pyrazin verbindungen als atr kinase inhibitoren
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776420A1 (de) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazinverbindungen als atr-kinaseinhibitoren
DE102011119127A1 (de) 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
LT2812337T (lt) 2012-02-09 2016-11-25 Merck Patent Gmbh Furo[3,2-b]piridino dariniai, kaip tbk1 ir ikk inhibitoriai
PL2833973T3 (pl) 2012-04-05 2018-02-28 Vertex Pharmaceuticals Incorporated Związki użyteczne jako inhibitory kinazy ATR i ich terapie skojarzone
EP2904406B1 (de) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Verfahren zur bestimmung der durch atr-inhibition auftretenden vermehrten dna-schädigung
WO2014062604A1 (en) 2012-10-16 2014-04-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
BR112015012454B1 (pt) 2012-12-07 2022-07-05 Vertex Pharmaceuticals Incorporated Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SG11201604519PA (en) 2013-12-06 2016-07-28 Vertex Pharma 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
EP3152212B9 (de) 2014-06-05 2020-05-27 Vertex Pharmaceuticals Inc. Radiomarkierte derivate von 2-amino-6-fluor-n-[ 5-fluor-pyridin-3-yl ]-pyrazolo [ 1,5-a ] pyrimidin-3-carboxamid-verbindung verwendbar als atr-kinase-inhibitor, herstellung der verbindung und unterschiedlichen raumformen davon
WO2015195740A1 (en) 2014-06-17 2015-12-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
EP3220910B1 (de) * 2014-11-18 2020-01-15 Merck Sharp & Dohme Corp. Aminopyrazinverbindungen mit a2a-antagonistischen eigenschaften
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA26473A1 (fr) 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.
DK1255740T3 (da) * 2000-02-16 2006-02-06 Neurogen Corp Substituerede arylpyraziner
EP1263745B1 (de) * 2000-03-07 2004-05-19 Aventis Pharma Deutschland GmbH Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one und ihre verwendung zur hemmung der hormonsensitiven lipase
AR029489A1 (es) * 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
CA2443724C (en) * 2001-05-11 2009-11-03 Patrizia Caldirola Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
JP2003081937A (ja) * 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
SE0203752D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
CN1729185A (zh) 2006-02-01
US7585853B2 (en) 2009-09-08
EP2161265A2 (de) 2010-03-10
JP4674088B2 (ja) 2011-04-20
NZ540449A (en) 2008-02-29
WO2004055005A8 (en) 2005-06-30
DE60330910D1 (de) 2010-02-25
US20060116362A1 (en) 2006-06-01
BR0317294A (pt) 2005-11-08
JP2006513180A (ja) 2006-04-20
IL169016A (en) 2013-08-29
EP1575938B1 (de) 2010-01-06
NO20053460L (no) 2005-08-12
KR20050084363A (ko) 2005-08-26
SE0203754D0 (sv) 2002-12-17
AU2003287135B2 (en) 2007-01-25
HK1080856A1 (en) 2006-05-04
ES2337682T3 (es) 2010-04-28
US20100075989A1 (en) 2010-03-25
ZA200504617B (en) 2006-03-29
NO331495B1 (no) 2012-01-16
MXPA05006243A (es) 2005-08-19
EP2161265A3 (de) 2010-06-02
KR101110457B1 (ko) 2012-02-17
AU2003287135A1 (en) 2004-07-09
CA2508042A1 (en) 2004-07-01
EP1575938A1 (de) 2005-09-21
CN100351250C (zh) 2007-11-28
WO2004055005A1 (en) 2004-07-01
CA2508042C (en) 2012-01-10

Similar Documents

Publication Publication Date Title
ATE454382T1 (de) Verbindungen mit selektiverinhibierender wirkung für gsk3
AR034268A1 (es) Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
HUP0400636A2 (hu) Azetidinszármazékokat tartalmazó gyógyszerkészítmények, új azetidinszármazékok és előállításuk
MXPA03007249A (es) Compuestos triazolo como inhibidores de mmp.
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
GEP20063890B (en) Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
UY27368A1 (es) Nuevos compuestos
AR032781A1 (es) Amidas ariladas de acidos furan- y tiofencarboxilicos, composiciones farmaceuticas, su utilizacion para la preparacion de medicamento como tambien las composiciones farmaceuticas que las contienen
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
MXPA04000456A (es) Analogos de prostaglandina como agonistas del receptor ep4.
NO20045486L (no) Nye forbindelser og deres anvendelse
AR036045A1 (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, su empleo para la preparacion de un medicamento, asi como composiciones farmaceuticas que las contienen
NO20015172L (no) 1-metyl-erytromycin-derivater
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
NO20060383L (no) Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister
DZ1694A1 (fr) "n-(2-Aminoethyl)-benzothialozones".
GEP20053505B (en) Diphenyl Ether Compounds Useful in Therapy
AU8799201A (en) Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases
SE0201194D0 (sv) New compounds
SE0102440D0 (sv) New compound
MXPA04005313A (es) Derivados de aminotetralin como antagonistas del receptor muscarinico.
HUP0203275A2 (hu) 1-(Gyűrűs amino)-alkilciklohexán-származékok, ezeket tartalmazó görcsoldó hatású gyógyszerkészítmények, valamint ezek alkalmazása
HUP0303195A2 (hu) O-helyettesített-6-metil-tramadol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
SE0203753D0 (sv) New compounds
UY27324A1 (es) Nuevas sales de napsilato i

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties